IL17A and psoriasis: In the Lan-Tu-Ya Wu et al. study, 12 patients with moderate and severe forms of psoriasis were enrolled, treated with Secukinumab, and their serum levels of TNF-α, IL-17A, and IL-23 were determined before and after treatment (moment established as patients achieving a PASI score below 1).